Innovative Technologies and Nonprescription Medications: Addressing Undertreated Diseases and Conditions through Technology Enabled Self-Care
On May 9, the Engelberg Center for Health Care Reform convened an expert workshop “Innovative Technologies and Nonprescription Medications: Addressing Undertreated Diseases and Conditions through Technology Enabled Self-Care.”
Recognizing the public health impact of undertreatment of common diseases and conditions, the U.S. Food and Drug Administration is exploring how a regulatory expansion of the nonprescription drug class might increase access to important medications and treatments. This initiative is referred to as Nonprescription Safe Use Regulatory Expansion (NSURE).
At this meeting, a wide range of experts and stakeholders explored the use of technologies as a condition to the safe use of medications within a nonprescription setting, discussed perspectives on the role of technology to support the safe and effective use of nonprescription products, and explored the integration of innovative technologies into the health care delivery system.
This expert workshop was the second in a series of meetings that will explore the NSURE initiative. To explore previous discussion regarding the potential role of health care professionals as a condition of safe use within the NSURE paradigm, please visit our expert workshop, “Nonprescription Medications with Conditions of Safe Use as a Novel Solution for Undertreated Diseases or Conditions”
Agenda
Welcome, Introduction and Expert Workshop Objectives
Opening Remarks
Rachel Sherman
Principal, Drug and Biological Drug Products - Greenleaf Health LLC
Role of Technology in Facilitating the Safe and Effective Use of Nonprescription Drugs
R. William Soller
Executive Director and Health Sciences Clinical Professor of Pharmacy - Center for Consumer Self Care and University of California, San Francisco
Session I: Using Innovative Technologies as a Condition of Safe Use
David Schifkovitz
Vice President, Regulatory Affairs, Wellness Category and North America - GlaxoSmithKline Consumer Healthcare
Erin Oliver
Director, Regulatory Affairs - GlaxoSmithKline Consumer Healthcare
Lannie Richardson
Chief Executive Officer - Central Control, Inc.
Malay Gandhi
Chief Strategy Officer - Rock Health
Donald Reitberg
Vice President - Farmacia Electronica, Inc.
Session II: Perspectives on the Role of Technologies as a Condition of Safe Use
Edwin Hemwall
Vice President - Global R&D, Rx-to-OTC Switch and New Opportunity Evaluation, Merck Consumer Care
Mark Gelbert
Senior Vice President, Global R&D and Switch - Pfizer Consumer Healthcare
Doris Peter
Director, Health Ratings Center - Consumer Health Choices
Closing Remarks
Session III: Integrating Technologies as a Condition of Safe Use into Nonprescription Health Care Delivery Systems
James Owen
Associate Vice President, Practice and Science Affairs - American Pharmacists Association
Shelly Spiro
Executive Director - Pharmacy e-Health Information Technology Collaborative
Edward Fotsch
Chief Executive Officer - PDR Network
Dan Luce
National Director, Pharmacy Affairs - Walgreens
More Information
To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.